Treatment with clobetasol propionate 0.025% topical therapy in various dermatoses


  • Ashwini Guttedar Department of Dermatology, Derma Care and cosmetic clinic, Warangal, Telangana, India
  • Nitin Mishra Department of Dermatology, Dr Nitin Mishra skin clinic and laser centre, Bareilly, Uttar Pradesh, India
  • Sanjay Kumar Gupta Department of Dermatology, Noble Medical Centre, Hyderabad, Telangana, India
  • Atul Dilip Mohankar Department of Dermatology, Chhattisgarh Institute of Medical Sciences, Bilaspur, Chhattisgarh, India
  • Karan Sancheti Department of Dermatology, NRG Polyclinic, Kolkata, West Bengal, India
  • Kanchan Srivastava Department of Dermatology, The Doctor’s Arena, Lucknow, Uttar Pradesh, India
  • Puja Sharma Department of Dermatology, TT Hospital, Kota, Rajasthan, India
  • Ashok Gangwar Department of Dermatology, Gangwar Skin & Fue Hair Transplant Center, Raipur, Chhattisgarh, India
  • Apoorva Jain Department of Dermatology, MAX Skin Care Centre, Bhopal, Madhya Pradesh, India
  • Lakshmi Sitara Ganisetti Department of Dermatology, Advanced Skin and Hair Clinic, Hyderabad, Telangana



CP 0.025%, Plaque psoriasis, Psoriasis, TCs


Owing to their anti-inflammatory and vasoconstrictive properties. Topical corticosteroids (TCs) provide benefits in various dermatological conditions, including atopic eczema, psoriasis, chronic hand eczema, and localized vitiligo. Clobetasol propionate (CP) is the most common topical agent possessing anti-inflammatory, antimitotic, antipruritic, and immunosuppressive properties that are employed in the management of plaque psoriasis. CP 0.025% cream was approved by the United States food and drug administration for the treatment of moderate-to-severe psoriasis in adult patients. The formulation is free from known contact allergens, such as propylene glycol, short-chain alcohols, and sorbitol-based emulsifiers, and has demonstrated hypoallergenic effects. High penetration of active ingredients and a lower degree of systemic absorption make CP 0.025% an effective and safe agent. This case series discusses the clinical experience of using CP 0.025% cream in various dermatologic conditions, focusing on its efficacy and safety.

Author Biography

Lakshmi Sitara Ganisetti, Department of Dermatology, Advanced Skin and Hair Clinic, Hyderabad, Telangana

Department of Dermatology, Advanced Skin and Hair Clinic, Hyderabad, Telangana


Del Rosso JQ. Topical corticosteroid therapy for psoriasis-a review of clobetasol propionate 0.025% cream and the clinical relevance of penetration modification. J Clin Aesthet Dermatol. 2020;13(2):22-9.

Uva L, Miguel D, Pinheiro C. Mechanisms of action of topical corticosteroids in psoriasis. Int J Endocrinol. 2012;2012;561018.

Zampetti A, Feliciani C, Tulli A. Pharmacotherapy of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses focus on clobetasol propionate. Clin Med Insights Ther. 2010;2:523-37.

Gottlieb AB, Ford RO, Spellman MC. The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of non-scalp regions. J Cutan Med Surg. 2003;7(3):185-92.

Draelos ZD, Fowler JF, Cornelison R. A randomized, parallel group, open label, multicenter study to assess the potential for adrenal suppression and systemic drug absorption following multiple dosing with clobetasol propionate cream (Impoyz™), 0.025% versus clobetasol propionate (Temovate®). J Cutan Med Surg. 2018;2(6):410-20.




How to Cite

Guttedar, A., Mishra, N., Gupta, S. K., Mohankar, A. D., Sancheti, K., Srivastava, K., Sharma, P., Gangwar, A., Jain, A., & Ganisetti, L. S. (2021). Treatment with clobetasol propionate 0.025% topical therapy in various dermatoses. International Journal of Research in Medical Sciences, 10(1), 250–256.



Case Series